Here, we found that genetic depletion or pharmacologic inhibition of PIKfyve upregulated surface expression of MHC-I in cancer cells, leading to enhanced antigen presentation and improved CD8+ T cell–mediated cancer cell killing in vitro. The gene discussed is CD8A; the disease is cancer.